Carballo‐Folgoso L, Álvarez‐Velasco R, Lorca R, et al. - Researchers conducted this observational retrospective study to evaluate the frequency and management of cardiovascular events in hepatocellular carcinoma (HCC) patients treated with sorafenib (SOR), as well as to develop a scale to anticipate the onset of major adverse cardiovascular events (MACE). The sample consisted of consecutive HCC patients treated with SOR between 2007 and 2019 in a western centre. Two hundred ninety‐nine patients were involved (219 BCLC‐C). Data reported that the median overall survival was 11.1 months and the duration of treatment was 7.4 months. The only independent factor associated with MACE was age. Cardiovascular events occur at a higher rate than expected in HCC patients treated with SOR. A multidisciplinary approach and clinical tools such as the CARDIOSOR scale could be beneficial to manage these patients.